Caplin Point Laboratories Limited declared an interim dividend of ₹4 per equity share on May 14, 2026, following its board meeting that also approved financial results for the quarter and year ended March 31, 2026. The announcement was made to NSE at 13:23 IST, marking the company's highest interim dividend payout in at least five years of available dividend history.

Dividend Details and Yield

The interim dividend of ₹4 per share translates to a dividend yield of approximately 0.22% based on the last traded price of ₹1,814.10 on NSE. With a market capitalisation of ₹13,812.09 Cr, the total dividend outflow will depend on the company's outstanding share count. The record date and payment date for this dividend have not yet been specified in the exchange filing.

Year-on-Year Comparison

Comparing this payout to the corresponding interim dividend from May 2024, when the board had declared ₹2.50 per share, the current interim dividend represents a 60% increase year-on-year. In FY24, the company paid a total dividend of ₹5 per share across interim and final tranches (₹2.50 + ₹2.50). If the board follows a similar pattern and declares a final dividend in August 2026, the full-year payout could exceed the FY25 total of ₹6.50 per share (₹3 final in August 2025 with no interim declared that year).

Dividend History and Trend

Caplin Point has maintained a consistent dividend track record over the past five years. The payout trend shows a clear upward trajectory:

The absence of an interim dividend in FY25, followed by a higher-than-usual interim payout in FY26, suggests a resumption of the company's two-tranche distribution structure with an elevated base.

Market Context and Valuation

Caplin Point shares closed at ₹1,814.10, down ₹27.70 or 1.50% on the day of the announcement. The stock trades at a price-to-earnings ratio of 22.51, which is in line with the sector PE of 22.51, indicating the stock is currently valued at par with its pharmaceutical peer group. The 52-week range stands at ₹1,500.30 (low on March 30, 2026) to ₹2,395 (high on September 17, 2025), placing the current price approximately 24% below the 52-week peak and about 21% above the 52-week low.

Trading Activity and Delivery Data

On the day of the announcement, 26,456 shares were traded on NSE with a delivery percentage of 63.52%, indicating that a majority of the day's trades resulted in actual delivery rather than intraday squaring off. This elevated delivery ratio relative to typical speculative sessions suggests a degree of conviction among participants transacting in the stock around the results and dividend announcement. Daily volatility stood at 2.24%.

Company Profile

Caplin Point Laboratories is a Chennai-based pharmaceutical company with a significant presence in Latin American and Francophone African markets. It is part of multiple NSE indices including NIFTY 500, NIFTY SMALLCAP 250, and NIFTY500 HEALTHCARE, reflecting its position as a recognised constituent across broad-market and sector-specific benchmarks.

Investors holding shares as of the yet-to-be-announced record date will be eligible to receive the ₹4 interim dividend. The company is expected to release further details including the record date in a subsequent exchange filing.